TopoTarget Stock Surges on Trickle of Data for Belinostat
By Cormac Sheridan
Tuesday, March 5, 2013
Without revealing much in the way of new data, TopoTarget A/S enjoyed a 45 percent bounce in its share price in early trading Tuesday, as an analysis of the final top-line results from a registration trial of belinostat in patients with relapsed or refractory peripheral T-cell lymphoma confirmed the drug exceeded the efficacy level defined by the study's primary endpoint.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.